+Compare
AEZS
Stock ticker:
NASDAQ
AS OF
Jul 1 closing price
Price
$0.22
Change
+$0.02 (+10.00%)
Capitalization
24.52M

AEZS Price Prediction, Aeterna Zentaris AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jul 01, 2022

AEZS saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for AEZS moved out of overbought territory on June 28, 2022. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 42 similar instances where the indicator exited the overbought zone. In 39 of the 42 cases the stock moved lower. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AEZS moved out of overbought territory on June 30, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

AEZS moved below its 50-day moving average on June 30, 2022 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEZS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AEZS broke above its upper Bollinger Band on June 29, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AEZS entered a downward trend on June 28, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 27, 2022. You may want to consider a long position or call options on AEZS as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AEZS just turned positive on May 26, 2022. Looking at past instances where AEZS's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AEZS advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AEZS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.494) is normal, around the industry mean (24.469). P/E Ratio (0.000) is within average values for comparable stocks, (93.841). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.919). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (5.136) is also within normal values, averaging (306.529).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEZS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

AEZS is expected to report earnings to rise 50.00% to -2 cents per share on August 11

Aeterna Zentaris AEZS Stock Earnings Reports
Q2'22
Est.
$-0.03
Q1'22
Est.
$-0.02
Q4'21
Est.
$-0.02
Q3'21
Beat
by $0.01
Q4'20
Beat
by $0.06
The last earnings report on May 11 showed earnings per share of -1 cents, meeting the estimate of -1 cents. With 1.37M shares outstanding, the current market capitalization sits at 24.52M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.73B. The market cap for tickers in the group ranges from 2.5K to 250.34B. NONOF holds the highest valuation in this group at 250.34B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -0%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was -36%. EVFM experienced the highest price growth at 145%, while PCNTD experienced the biggest fall at -81%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -54%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 94
Seasonality Score: -18 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
c/o Norton Rose Fulbright Canada, LLP
Phone
N/A
Employees
17
Web
https://www.zentaris.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SP31.610.89
+2.90%
SP Plus Corp
DGX136.683.70
+2.78%
Quest Diagnostics
FBP13.260.35
+2.71%
First BanCorp
XELB1.190.01
+0.85%
Xcel Brands
ALPA9.700.02
+0.21%
Alpha Healthcare Acquisition Corp

AEZS and

Correlation & Price change

A.I.dvisor indicates that over the last year, AEZS has been loosely correlated with ALNA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AEZS jumps, then ALNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AEZS
1D Price
Change %
AEZS100%
+9.81%
ALNA - AEZS
49%
Loosely correlated
+10.99%
ADTX - AEZS
45%
Loosely correlated
+1.82%
CMRX - AEZS
42%
Loosely correlated
+2.88%
NBRV - AEZS
39%
Loosely correlated
-1.04%
ONVO - AEZS
38%
Loosely correlated
-0.56%
More